BN Business News
Add your company to Business Communicator →

Business · 20/11/20261 min read

SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry interest in next-generation engineered T-cell platforms

Original source language: GlobeNewswire — Mergers and AcquisitionsOpen original release →

Explore insights

Business insights →